Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations

Clinical Pharmacokinetics

Volumn 53, Issue 3, 2014, Pages 283-293

  Hsu, Vicky ^a   Vieira, Manuela De L T ^a,b   Zhao, Ping ^a   Zhang, Lei ^a   Zheng, Jenny Huimin ^a   Nordmark, Anna ^c   Berglund, Eva Gil ^c   Giacomini, Kathleen M ^d   Huang, Shiew Mei ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CEFUROXIME; CIDOFOVIR; OSELTAMIVIR; PROBENECID; CARRIER PROTEIN; DRUG; URINARY TRACT AGENT;

AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG UPTAKE; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHILICITY; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; KIDNEY TUBULE EXCRETION; NEPHROTOXICITY; NORMAL HUMAN; PARTITION COEFFICIENT; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; SIMULATION; SIMULATOR; STEADY STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COMPUTER SIMULATION; KIDNEY; KIDNEY DISEASE; METABOLISM;

ANIMALS; COMPUTER SIMULATION; HUMANS; KIDNEY; KIDNEY DISEASES; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROBENECID; RENAL AGENTS;

EID: 84896887676     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0117-y     Document Type: Article

References (31)

1. Neuhoff S, Gaohua L, Burt H, Jamei M, Li L, Tucker GT, Rostami-Hodjegan A. Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM). In: Steffanson B, Sugiyama Y, editors. Transporters in drug discovery, development, and use. New York: Springer; 2013 (in press).
2. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52:4844-52.
3. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259-76. (Pubitemid 40904190)
4. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238-57. (Pubitemid 43874439)
5. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet. 2009;24:53-75.
6. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4:261-74.
7. Multiple ascending oral dose study of the pharmacokinetics, tolerability, and safety of the neuraminidase inhibitor Ro 64-0796 in subjects with renal impairment. Clinical Pharmacology and Biopharmaceutics Review from Drugs@FDA; 1999.
8. Bundtzen RW, Toothaker RD, Nielson OS, Madsen PO, Welling PG, Craig WA. Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother. 1981;19:443-9. (Pubitemid 11119389)
9. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36:127-43. (Pubitemid 29121686)
10. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007;321:673-83. (Pubitemid 46624514)
11. Cutler MJ, Urguhart BL, Velenosi TJ, Meyer zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012;52:530-42.
12. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002;30:13-9. (Pubitemid 34016935)
13. Cidofovir (US label); 2013. http://www.accessdata.fda.gov/drugsatfda- docs/label/1999/020638s003lbl.pdf.
14. Cidofovir (EMA summary for the public); 2013. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/ 000121/WC500052073.pdf.
15. Stuart & Ord. Kendall's advanced theory of statistics, 6th ed. London: Arnold; 1998.
16. Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, Arya V, Berglund EG, Atkinson Jr AJ, Sugiyama Y, Pang KS, Reynolds KS, Abernethy DR, Zhang L, Lesko LJ, Huang SM. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52:91S-108S.
17. Bohle A, Christ H, Grund KE, Mackensen S. The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol. 1979;16:109-14.
18. Dixon RJ, Young K, Brunskill NJ. Lysophosphatidic acid-induced calcium mobilization and proliferation in kidney proximal tubular cells. Am J Physiol. 1999;276:F191-8. (Pubitemid 29102283)
19. Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996;27:765-75. (Pubitemid 26169027)
20. Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol. 1989;135:719-33. (Pubitemid 19268030)
21. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 1995;47:1546-57.
22. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol. 1993;13:385-98. (Pubitemid 24014486)
23. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213-7. (Pubitemid 43323069)
24. Villar SR, Brandoni A, Anzai N, Endou H, Torres AM. Altered expression of rat renal cortical OAT1 and OAT3 in response to bilateral ureteral obstruction. Kidney Int. 2005;68:2704-13. (Pubitemid 43251015)
25. Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos. 2004;32:1096-102. (Pubitemid 39287583)
26. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of organic anion transport inhibitors using cells stably expressing human anion transporters. Eur J Pharmacol. 2001;419:113-20. (Pubitemid 32568209)
27. Parrott N, Davies B, Hoffman G, Koerner A, Lave T, Prinssen E, Theogaraj E, Singer T. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet. 2011;50:613-23.
28. Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother. 1976;9:741-7.
29. Study of the pharmacokinetics and absolute bioavailability of the neuraminidase inhibitor Ro 64-0796/Ro 64-0802 (Protocol NP15719). Clinical Pharmacology and Biopharmaceutics Review from Drugs@FDA; 1999.
30. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999;65:21-8. (Pubitemid 29062025)
31. Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. J Antimicrob Chemother. 1997;40:903-6. (Pubitemid 28022160)